natgillin/translations-raw huggingface dataset:
Prialt не се препоръчва за употреба при деца и юноши.
Prialt is not recommended for use in children and adolescents.
Prialt се използва за лечение на много силна дългосрочна болка при възрастни, които се нуждаят от болкоуспокояващо, поставено чрез интратекална инжекция (инжекция в пространството около гръбначния стълб).
Prialt is used for the treatment of severe, long-term pain in adults who need a painkiller by intrathecal injection (injection into the space that surrounds the spinal cord and the brain).
Prialt съдържа активното вещество зиконотид, което принадлежи към група лекарства, наречени аналгетици или „болкоуспокояващи”.
Prialt contains the active substance ziconotide which belongs to a group of medicines, called analgesics or ‘painkillers’.
Približno 60% bolnikov se je že zdravilo s konvencionalno sistemsko terapijo ali fototerapijo.
Approximately 60% of the patients had prior exposure to conventional systemic therapy or phototherapy.
Približno 62 % palonosetrona je vezanega na plazemske proteine.
Approximately 62 % of palonosetron is bound to plasma proteins.
Približno 80% bolnikov iz 1. študije PsA (PSUMMIT 1) in 86% bolnikov iz 2. študije PsA (PSUMMIT 2) je bilo že zdravljenih z DMARDs.
In PsA Study 1 (PSUMMIT I) and PsA Study 2 (PSUMMIT II), 80% and 86% of the patients, respectively, had been previously treated with DMARDs.
Približno 90 % odmerka, označenega s 14C, se izloči skozi ledvica, medtem ko v fecesu najdemo manj kot 2 % odmerka.
Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Približno 97 % meloksikama se veže na beljakovine v plazmi.
Approximately 97 % of meloxicam is bound to plasma proteins.
Pridobljen Fanconijev sindrom
Acquired Fanconi syndrome
Priemerný vek pacientov bol 56 rokov (rozsah 17 až 81 rokov), 30 % boli muži, 77 % belosi, 12 % Afroameričania a 4 % Ázijci.
The median patient age was 56 years (range 17 to 81), 30% were male, 77% Caucasian, 12% African American and 4% Asian.
Priestley Road Basingstoke Hampshire RG24 9NL
Basingstoke Hampshire RG24 9NL
Prikazana pogostnost navedb je skladna s CTCAE, verzija 3.0.
The reporting rates shown are according to CTCAE version 3.0.
Priključitev na jeklenko in na napeljavo respiratorja za dihanje.
Connections to the gas cylinder and to the ventilator patient breathing circuit
PRILACTONE се използва в комбинация със „стандартна терапия’’ (други сърдечни лекарства, включително и диуретици, ако е необходимо).
PRILACTONE is used in combination with ‘standard therapy’ (other heart medicines, including diuretic support where necessary).
Prilagajanja odmerkov
Dose adjustments
Prilagoditev odmerka pri bolnikih z jetrno odpovedjo verjetno ni potrebna, ker se približno 90 % absorbirane zdravilne učinkovine izloči skozi ledvice.
Dose adjustment in patients with hepatic failure is probably not necessary, as approx.
Prilagoditev odmerka zdravila Teysuno za naslednji odmerek/cikel
Teysuno dose adjustment for next dose / next cycle
Prilagoditve med zdravljenjem
Adjustments during treatment
Prilaz baruna Filipovica 25 10000 Zagreb,
Prilaz baruna Filipovica 25 10000 Zagreb
PRILOGA II
ANNEX II‌
PRILOGA III
ANNEX III
PRILOGA III OZNAČEVANJE IN NAVODILO ZA UPORABO
LABELLING AND PACKAGE LEAFLET
PRILOGA IV
Annex IV
Prilokain, dan bodisi v peroralni, parenteralni ali topikalni obliki, lahko povzroči methemoglobinemijo.
Prilocaine, whether administered as oral, parenteral, or topical formulations may cause methaemoglobinaemia.
Primarni cilj je bil delež bolnikov, ki so v 12. tednu dosegli oceno PGA čisto (0) ali minimalno (1).
The primary endpoint was the proportion of patients who achieve a PGA score of cleared (0) or minimal (1) at week 12.
Primarni cilj je bila sprememba indeksa SES-CD (Simplified Endoscopic Disease Severity Score for Crohn’s Disease) glede na izhodiščno vrednost, t.j. skupna ocena 5 ileo-količnih segmentov glede prisotnosti/velikosit razjed; deleža površine sluznice, ki ga predstavljajo razjede; deleža površine sluznice, ki ga predstavljajo druge lezije in prisotnosti/vrste zoženja/strikture.
The primary endpoint was change from baseline in Simplified Endoscopic Disease Severity Score for Crohn’s Disease (SES-CD), a composite score across 5 ileo- colonic segments of presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions and presence/type of narrowing/strictures.
Primarni končni rezultat glede celokupnega preživetja pri zdravilu Teysuno v kombinaciji s cisplatinom ni bil slabši kot pri 5-FU v kombinaciji s cisplatinom (glejte Preglednico 9).
For the primary endpoint of overall survival, Teysuno in combination with cisplatin was non-inferior to 5-FU in combination with cisplatin (see Table 9).
Primarni končni rezultat je bil delež bolnikov, ki so po 24. tednih dosegli odziv 20 po merilih Ameriškega revmatološkega združenja (ACR-American College of Rheumatology criteria).
The primary endpoint was the percentage of patients who achieved American College of Rheumatology (ACR) 20 response at week 24.
Primarni končni rezultat v teh študijah je bil delež bolnikov, ki so od začetka študije do 12. tedna dosegli odziv PASI 75 (glejte preglednici 4 in 5).
The primary endpoint in these studies was the proportion of patients who achieved PASI 75 response from baseline at week 12 (see Tables 4 and 5).
Primarni opazovani dogodek je bil opažen pri 15,0 % bolnikov v skupini s klopidogrelom in 21,7 % bolnikov v skupini s placebom, kar predstavlja absolutno zmanjšanje za 6,7 % in 36 % zmanjšanje verjetnosti v prid klopidogrela (95 % IZ od 24 % do 47 %; p<0,001) v glavnem zaradi zmanjšanja pojavnosti zaradi infarkta zamašenih arterij.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries.
Primarni opazovani dogodek študije je bila odstotna sprememba mineralne gostote kosti (MGK) v ledveni hrbtenici po 12 mesecih zdravljenja v primerjavi z izhodiščem.
The primary endpoint of the study was the percent change from baseline in lumbar spine bone mineral density (BMD) after 12 months of treatment.
Primarni opazovani dogodki so bili navzočnost kompozita zaradi infarkta zamašene arterije na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography.
Primerjava 218 bolnikov z blago izhodiščno ledvično okvaro (CrCl 51–80 ml/min) in 297 bolnikov z normalno izhodiščno ledvično funkcijo (CrCl > 80 ml/min), zdravljenih z zdravilom Teysuno v kombinaciji s cisplatinom, v študiji FLAGS je pokazala, da med bolniki z blago ledvično okvaro in bolniki z normalno ledvično funkcijo ni bilo klinično pomembnih razlik glede varnosti.
Comparison of 218 patients with mild renal impairment at baseline (CrCl 51 to 80 ml/min) to 297 patients with normal renal function at baseline (CrCl >80 ml/min) treated with Teysuno in combination with cisplatin in the FLAGS study indicated that there were no clinically significant differences in safety between patients with mild renal impairment and patients with normal renal function.
Primerjava med krivuljama preživetja pri dveh zdravljenih skupinah z uporabo testa log rank je pokazala statistično pomembno razliko med krivuljama v obeh skupinah populacije ITT (p=0,0014), kar kaže na pomemben zastoj v napredovanju raka.
Comparison between the survival curves of the two treatment arms using the log rank test showed a statistically significant difference between the curves of the two groups in the ITT population (p=0.0014) indicating a significant delay in the progression to cancer.‌
Primerjava med krivuljama preživetja pri dveh zdravljenih skupinah z uporabo testa log rank je pokazala statistično pomembno razliko med krivuljama v obeh skupinah populacije ITT (p=0,0014), kar kaže na pomemben zastoj v napredovanju raka.
Comparison between the survival curves of the two treatment arms using the log rank test showed a statistically significant difference between the curves of the two groups in the ITT population (p=0.0014), indicating a significant delay in the progression to cancer.
Primerjava varnosti, izvedena med 71 bolniki, starimi 70 let ali več (starejši), in 450 bolniki, starimi manj kot 70 let, ki so bili zdravljeni z zdravilom Teysuno v kombinaciji s cisplatinom, v študiji FLAGS je pokazala, da so pogostnost vseh neželenih učinkov stopnje 3 ali višje stopnje (62 % proti 52 %), pogostnost vseh resnih neželenih učinkov (30 % proti 19 %) in količnik predčasnega umika tako zdravila Teysuno kot cisplatina zaradi neželenih učinkov (21 % proti 12 %) višji pri bolnikih, starih 70 let ali več.
Comparison of safety between 71 patients ≥70 years old (elderly) and 450 patients <70 years old treated with Teysuno in combination with cisplatin in the FLAGS study demonstrated that the incidence of all Grade 3 or higher adverse reactions (62% vs 52%), all serious adverse reactions (30% vs 19%), and the rate of premature withdrawal due to adverse reactions from both Teysuno and cisplatin (21% vs 12%) appeared to be higher among patients ≥70 years old.
Primerna mesta za injiciranje zdravila so zgornji del stegna ali trebuh (abdomen), in sicer najmanj 5 cm stran od popka.
Good places for the injection are the upper thigh or around the belly (abdomen) at least 5 cm away from the navel (belly button)
Primární parametrem účinnosti bylo celkové skóre ADHD-RS-IV.
The primary efficacy assessment was the ADHD-RS-IV total score.
Principiálně se atazanavir metabolizuje prostřednictvím CYP3A4.
Atazanavir is metabolised principally by CYP3A4.
Pripomočke, to je brizgo, iglo in antiseptične zložence, vato ali gazo ter vsebnik za odlaganje igel (glejte Sliko 1) položite na čisto površino.
This includes a syringe, needle, antiseptic wipes, a cotton ball or gauze, and a sharps container (see Figure 1).
Pripomočke, to je brizgo, iglo in antiseptične zložence, vato ali gazo ter vsebnik za odlaganje igel položite na čisto površino.
This includes antiseptic wipes, a cotton ball or gauze, and a sharps container.
Priporoča se genetsko svetovanje.
Genetic counseling should be considered.
Priporočamo ukrepe prosti zanositvi ali vzdržnost.
Contraceptive measures or abstinence are recommended.
Priporočamo uporabo rokavic.
The use of gloves is recommended.
Priporočamo zaščito proti zanositvi ali vzdržnost.
Contraceptive measures or abstinence are recommended.
Priporočene prilagoditve odmerkov zdravila Pemetreksed Hospira in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Hospira and cisplatin is documented in Table 3.
Priporočeni odmerek cisplatina je 75 mg/m2 TP, infundiran v dveh urah približno 30 minut po zaključku infuzije pemetrekseda prvi dan vsakega 21-dnevnega ciklusa.
The recommended dose of cisplatin is 75 mg/m2 BSA infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle.
Priporočeni odmerek PhotoBarra je 2 mg/kg telesne mase.
The recommended dose of PhotoBarr is 2 mg/kg body weight.
priporočeni odmerek ustekinumaba
Recommended dose of Ustekinumab
Priporočeni odmerek za hiperkalciemijo (za albumin korigirani serumski kalcij ≥ 12,0 mg/dl ali 3,0 mmol/l) je enkratni odmerek 4 mg zoledronske kisline.
The recommended dose in hypercalcaemia (albumin-corrected serum calcium ≥ 12.0 mg/dl or mmol/l) is a single dose of 4 mg zoledronic acid.
Priporočeni odmerek za preprečevanje z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti, je 4 mg zoledronske kisline vsake 3 do 4 tedne.
The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg zoledronic acid every 3 to 4 weeks.
Priporočeni odmerek zdravila Palonosetron Hospira 250 mikrogramov se daje kot hitra injekcija v veno.
The recommended dose of Palonosetron Hospira is 250 micrograms given as a rapid injection into a vein.
Priporočeni odmerek zdravila Pemetreksed Hospira je 500 mg/m2 telesne površine (TP), dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega ciklusa.
The recommended dose of Pemetrexed Hospira is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Priporočeni odmerek zdravila s cisplatinom pri tej shemi je 75 mg/m2 z intravenskim infundiranjem, ki se opravi enkrat na 4 tedne.
The recommended dose of cisplatin with this regimen is 75 mg/m2 by intravenous infusion administered once every 4 weeks.
Priporočeni odmerek zdravila STELARA glede na telesno maso je prikazan v spodnjih preglednicah (preglednici 1 in 2).
The recommended dose of STELARA based on body weight is shown below (Tables 1 and 2).
Priporočeni odmereka
Recommended dosea
Priporočeni standardni odmerek za bolnike z zmerno ledvično okvaro je 20 mg/m2 dvakrat dnevno (izraženo z vsebnostjo tegafurja) (glej poglavji 4.8 in 5.2).
The recommended standard dose in patients with moderate renal impairment is 20 mg/m2 twice daily (expressed as tegafur content) (see sections 4.8 and 5.2).
Priporočeni začetni odmerek zdravila STELARA je 45 mg (subkutana injekcija), ki mu sledi 45 mg odmerek čez 4 tedne in nato na vsakih 12 tednov.
The recommended posology of STELARA is an initial dose of 45 mg administered subcutaneously, followed by a 45 mg dose 4 weeks later, and then every 12 weeks thereafter.
Priporočeni začetni odmerek zdravila Stelara je 45 mg.
The recommended starting dose is 45 mg Stelara.
Priporočljivi so redni oftalmološki pregledi, še posebno, če se pojavijo motnje vida.
Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.
Priporočljivo je poiskati osnovni vzrok in žival ustrezno zdraviti.
It is advisable to determine the underlying cause and also treat the animal accordingly.
Priporočljivo je poiskati osnovni vzrok in žival ustrezno zdraviti.
It is advisable to determine the underlying cause and treat the animal accordingly.
Priporočljivo je, da se glede na reakcije posameznih bolnikov odmerjanje levodope zmanjša tako med povečevanjem odmerka zdravila Pramipeksol Accord kot med vzdrževalnim zdravljenjem z zdravilom Pramipeksol Accord (glejte poglavje 4.5).
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with Pramipexole Accord, depending on reactions in individual patients (see section 4.5).
Priporočljivo je, da se odmerek antikoagulantov na začetku zdravljenja zniža za eno tretjino in se nato po potrebi postopoma prilagodi v skladu s spremljanjem internacionalnega normaliziranega razmerja (INR – International Normalised Ratio).
It is recommended that the dose of anticoagulants is reduced by about one third at the start of treatment and then gradually adjusted if necessary according to INR (International Normalised Ratio) monitoring.
Priporočljivo je, da tega zdravila v nosečnosti ne uporabljate.
It is preferable not to use this medicine during pregnancy.
Priporočljivo je, da živih virusnih ali živih bakterijskih cepiv (na primer cepiva z Bacillusom Calmette-Guérin - BCG) ne dajete v času zdravljenja z zdravilom STELARA.
It is recommended that live viral or live bacterial vaccines (such as Bacillus of Calmette and Guérin (BCG)) should not be given concurrently with STELARA.
Priprava za uporabo napolnjene injekcijske brizge
Preparing for use of the pre-filled syringe
Pripravený roztok sa musí riediť infúznym roztokom chloridu sodného 9 mg/ml (0,9 %) alebo infúznym roztokom glukózy 50 mg/ml (5 %).
The reconstituted solution should be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.
Pripravený roztok vedie k číremu, bezfarebnému alebo až slabo žltému roztoku, v podstate bez viditeľných častíc.
The reconstituted solution results in a clear, colourless or slightly yellowish solution, essentially free of visible particles.
Pripravený roztok zrieďte infúznym roztokom chloridu sodného 9 mg/ml (0,9 %) alebo infúznym roztokom glukózy 50 mg/ml (5 %).
Dilute the reconstituted solution with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.
Pripravený roztok:
Reconstituted solution
Pripravite injekcijsko mesto
Prepare the injection site
Pripravite odmerek:
Prepare the dose:
Pritor 20 mg са бели кръгли таблетки, върху които е гравиран кодов номер 50Н от едната страна и фирмения знак от другата страна.
Pritor 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side.
Pritor 20 mg таблетки телмисартан
Pritor 20 mg tablets telmisartan
Pritor 40 mg са бели продълговати таблетки, гравирани с кодов номер 51H.
Pritor 40 mg tablets are white, oblong-shaped and engraved with the code '51H' on one side.
Pritor 40 mg таблетки телмисартан
Pritor 40 mg tablets telmisartan
Pritor 80 mg са бели продълговати таблетки, гравирани с кодов номер 52H.
Pritor 80 mg tablets are white, oblong-shaped and engraved with the code '52H' on one side.
Pritor 80 mg таблетки телмисартан
Pritor 80 mg tablets telmisartan
Pritor не се препоръчва в ранна бременност и не трябва да се приема след третия месец от бременността, тъй като може сериозно да увреди Вашето дете, ако се използва в този период (вижте раздел Бременност).
Pritor is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Pritor не се препоръчва в ранна бременност и не трябва да се приема, ако сте бременна след третия месец, тъй като може сериозно да увреди Вашето дете, ако се използва след третия месец от бременността.
Pritor is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Pritor не се препоръчва на майки, които кърмят и Вашият лекар може да Ви назначи друго лечение, ако искате да кърмите, особено ако Вашето дете е новородено или е родено преждевременно.
Pritor is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Pritor принадлежи към групата лекарствени продукти, известни като рецепторни антагонисти на ангиотензин ІІ.
Pritor belongs to a class of medicines known as angiotensin II receptor antagonists.
Pritor се предлага в блистери, съдържащи 14, 28, 28 х 1, 30, 56, 90, 98 или 280 таблетки.
Pritor is available in blister packs containing 14, 28, 30, 56, 90, 98 or 280 tablets, or unit dose blister packs containing 28 x 1 tablets.
PritorPlus 40 mg/12,5 mg
PritorPlus 40 mg/12.5 mg
PritorPlus 40 mg/12,5 mg може да се приложи един път дневно при пациенти, чието кръвно налягане не е адекватно контролирано при самостоятелно прилагане на Pritor 40 mg.
PritorPlus 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Pritor 40 mg
PritorPlus 40 mg/12,5 mg таблетки
PritorPlus 40 mg/12.5 mg tablets
PritorPlus 40 mg/12,5 mg таблетки телмисартан/хидрохлорoтиазид
PritorPlus 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
PritorPlus 80 mg/12,5 mg
PritorPlus 80 mg/12.5 mg
PritorPlus 80 mg/12,5 mg може да се приложи един път дневно при пациенти, чието кръвно налягане не е адекватно контролирано при самостоятелно прилагане на Pritor 80 mg.
PritorPlus 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Pritor 80 mg
PritorPlus 80 mg/12,5 mg таблетки телмисартан/хидрохлорoтиазид
PritorPlus 80 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
PritorPlus 80 mg/25 mg таблетки
PritorPlus 80 mg/25 mg tablets
PritorPlus 80 mg/25 mg таблетки телмисартан/хидрохлорoтиазид
PritorPlus 80 mg/25 mg tablets telmisartan/hydrochlorothiazide
PritorPlus е комбинация от две активни вещества в една таблетка – телмисартан и хидрохлорoтиазид.
PritorPlus is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet.
PritorPlus не се препоръчва в ранна бременност и не трябва да се приема след третия месец от бременността, тъй като може сериозно да увреди Вашето дете, ако се използва в този период (вижте раздел Бременност).
PritorPlus is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
PritorPlus не се препоръчва по време на бременност и не трябва да се приема, ако сте бременна след третия месец, тъй като може сериозно да увреди Вашето дете, ако се използва след третия месец от бременността.
PritorPlus is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
PritorPlus не трябва да се прилага при пациенти с тежко бъбречно увреждане (креатининов клирънс < 30 ml/min) (вж. точка 4.3).
PritorPlus should not be used in patients with severe renal impairment (creatinine clearance <30 ml/min) (see section 4.3).
PritorPlus представлява лекарство, съдържащо две активни вещества — телмисартан (telmisartan)и хидрохлоротиазид (hydrochlorothiazide).
PritorPlus is a medicine that contains two active substances, telmisartan and hydrochlorothiazide.
PritorPlus се предлага в блистери, съдържащи 14, 28, 30, 56, 90 или 98 таблетки или перфориран еднодозов блистер с 28 x 1 таблетки.
PritorPlus is available in blister packs containing 14, 28, 30, 56, 90 or 98 tablets, or unit dose blister packs containing 28 x 1 tablets
PritorPlus сепредлага още и в дози 40 mg/12,5 mg и 80 mg/12,5 mg.
PritorPlus is also available at the dose strengths 40 mg/12.5 mg and 80 mg/12.5 mg
PritorPlus съдържа две активни вещества — телмисартан и хидрохлоротиазид.
PritorPlus contains two active substances, telmisartan and hydrochlorothiazide.
PritorPlus трябва да се съхранява в запечатания блистер, поради хигроскопичните свойства на таблетките.
PritorPlus should be kept in the sealed blister due to the hygroscopic property of the tablets.
Privigen 100 mg/ml инфузионен разтвор
Privigen 100 mg/ml solution for infusion
Privigen 100 mg/ml инфузионен разтвор Човешки имуноглобулин, нормален (i.v.Ig)
Privigen 100 mg/ml solution for infusion Human normal immunoglobulin (IVIg)
Privigen действа, като възстановява анормално ниските нива на IgG (имуноглобулин G) до обичайната им стойност в кръвта.
Privigen works by restoring abnormally low IgG levels to their normal range in the blood.
Privigen е лекарство, което съдържа активното вещество човешки нормален имуноглобулин (human normal immunoglobulin).
Privigen is a medicine that contains the active substance human normal immunoglobulin.
Privigen е получен от човешка кръвна плазма (това е течната част на кръвта).
Privigen is made from human blood plasma (this is the liquid part of the blood).
Privigen е прилаган в два последователни дни.
Privigen was given on two consecutive days.
Privigen не е сравнен с други лечения в проучванията.
Privigen was not compared to other treatments in the studies.
Privigen не трябва да се прилага при пациенти с хиперпролинемия (генетично нарушение, причиняващо високи нива на аминокиселината пролин в кръвта).
Privigen must not be used in patients with hyperprolinaemia (a genetic disorder causing high levels of the amino acid proline in the blood).